PPAR Research

Peroxisome Proliferator-Activated Receptor δ, A Target with a Broad Therapeutic Potential for Drug Discovery


Publishing date
01 Dec 2008
Status
Published
Submission deadline
01 Jul 2008


Peroxisome Proliferator-Activated Receptor δ, A Target with a Broad Therapeutic Potential for Drug Discovery

Articles

  • Special Issue
  • - Volume 2008
  • - Article ID 736362
  • - Editorial

Peroxisome Proliferator-Activated Receptor δ: A Target with a Broad Therapeutic Potential for Drug Discovery

Francine M. Gregoire
  • Special Issue
  • - Volume 2008
  • - Article ID 164163
  • - Review Article

PPAR- in Vascular Pathophysiology

Nanping Wang
  • Special Issue
  • - Volume 2008
  • - Article ID 794814
  • - Review Article

The Potential Applications of Peroxisome Proliferator-Activated Receptor Ligands in Assisted Reproductive Technology

Jaou-Chen Huang
  • Special Issue
  • - Volume 2008
  • - Article ID 780452
  • - Review Article

Peroxisome Proliferator-Activated Receptor in the Brain: Facts and Hypothesis

M. G. Hall | Laure Quignodon | Béatrice Desvergne
  • Special Issue
  • - Volume 2008
  • - Article ID 125387
  • - Review Article

PPAR 𝜹 Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities

Mylène Perreault | David V. Erbe | James F. Tobin
  • Special Issue
  • - Volume 2008
  • - Article ID 172676
  • - Review Article

Peroxisome Proliferator-Activated Receptor Delta: A Conserved Director of Lipid Homeostasis through Regulation of the Oxidative Capacity of Muscle

Pieter de Lange | Assunta Lombardi | ... | Maria Moreno
  • Special Issue
  • - Volume 2008
  • - Article ID 614852
  • - Review Article

Regulation of Cell Proliferation and Differentiation by PPAR

Rolf Müller | Markus Rieck | Sabine Müller-Brüsselbach
PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore7.100
Impact Factor2.953
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.